From Bedside to Bench to Bedside to Clinical Practice: An Odyssey with Irinotecan

This publication has 15 references indexed in Scilit:

• Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer
  Cancer Chemotherapy and Pharmacology, 2005
• Managing Familial Risk in Genetic Testing
  Genetic Testing, 2004
• UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer*1
  Clinical Pharmacology & Therapeutics, 2004
• Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of Irinotecan
  Journal of Clinical Oncology, 2004
• UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
  The Pharmacogenomics Journal, 2002
• Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism
  Clinical Pharmacology & Therapeutics, 1999
• Racial variability in the UDP-glucuronosyltransferase 1 ( UGT1A1 ) promoter: A balanced polymorphism for regulation of bilirubin metabolism?
  Proceedings of the National Academy of Sciences, 1998
• Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.
  Journal of Clinical Investigation, 1998
• Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome
  The Lancet, 1996
• The Genetic Basis of the Reduced Expression of Bilirubin UDP-Glucuronosyltransferase 1 in Gilbert's Syndrome
  New England Journal of Medicine, 1995